S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Bed Bath & Beyond Is Circling the Drain
Pfizer Stock: What the Bulls and Bears are Getting Wrong
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Institutions are Buying up Procter & Gamble Shares, Should you?
Has The Salesforce Turnaround Begun?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Bed Bath & Beyond Is Circling the Drain
Pfizer Stock: What the Bulls and Bears are Getting Wrong
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Institutions are Buying up Procter & Gamble Shares, Should you?
Has The Salesforce Turnaround Begun?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Bed Bath & Beyond Is Circling the Drain
Pfizer Stock: What the Bulls and Bears are Getting Wrong
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Institutions are Buying up Procter & Gamble Shares, Should you?
Has The Salesforce Turnaround Begun?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Bed Bath & Beyond Is Circling the Drain
Pfizer Stock: What the Bulls and Bears are Getting Wrong
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Institutions are Buying up Procter & Gamble Shares, Should you?
Has The Salesforce Turnaround Begun?
NASDAQ:IMCR

Immunocore - IMCR Stock Forecast, Price & News

$62.41
+1.14 (+1.86%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$60.00
$63.21
50-Day Range
$51.43
$63.74
52-Week Range
$21.00
$69.06
Volume
231,025 shs
Average Volume
289,496 shs
Market Capitalization
$2.74 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$78.25

Immunocore MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
26.8% Upside
$79.13 Price Target
Short Interest
Bearish
4.11% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.17mentions of Immunocore in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.49) to ($0.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

821st out of 1,053 stocks

Biological Products, Except Diagnostic Industry

133rd out of 170 stocks


IMCR stock logo

About Immunocore (NASDAQ:IMCR) Stock

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Receive IMCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter.

IMCR Stock News Headlines

The Biggest "Missing Ingredient" in the $7 Trillion EV Market
China has owned the graphite market for decades. But the U.S. just added graphite to a list of super-critical minerals... "essential for America's National Defense." Perfect timing for a "made in America" graphite company looking to mine, manufacture, and recycle graphite for the booming electric car market.
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
3 Drug Stocks Most Wall Street Analysts Are Bullish About
7 Analysts Have This to Say About Immunocore Hldgs
Analyst Ratings for Immunocore Hldgs
Are Medical Stocks Lagging Immunocore (IMCR) This Year?
Are Medical Stocks Lagging Immunocore (IMCR) This Year?
See More Headlines
Receive IMCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter.

IMCR Company Calendar

Last Earnings
11/09/2022
Today
2/02/2023
Next Earnings (Estimated)
3/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMCR
Fax
N/A
Employees
324
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$79.13
High Stock Price Forecast
$90.00
Low Stock Price Forecast
$67.00
Forecasted Upside/Downside
+25.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$-180,860,000.00
Pretax Margin
-64.48%

Debt

Sales & Book Value

Annual Sales
$35.80 million
Book Value
$5.38 per share

Miscellaneous

Free Float
41,467,000
Market Cap
$2.74 billion
Optionable
Not Optionable
Beta
0.57

Key Executives

  • Dr. Bahija Jallal Ph.D. (Age 61)
    CEO & Director
    Comp: $1.27M
  • Mr. Brian R. Di Donato M.B.A. (Age 56)
    CFO & Head of Strategy
  • Ms. Annelise Vuidepot Ph.D.
    CTO and Head of Pipeline & Platform Research
  • Clayton Robertson
    Head of Investor Relations
  • Ms. Lily Hepworth
    Gen. Counsel & Company Sec.
  • Ms. Amy Judge-Prein
    Chief Compliance Officer
  • Mr. Sébastien Desprez
    Head of Communications
  • Ms. Tina St. Leger (Age 54)
    Chief HR Officer
  • Dr. David Berman M.D. (Age 52)
    Ph.D., Head of R&D
  • Ms. Debra Nielsen
    Chief of Staff













IMCR Stock - Frequently Asked Questions

Should I buy or sell Immunocore stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunocore in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMCR shares.
View IMCR analyst ratings
or view top-rated stocks.

What is Immunocore's stock price forecast for 2023?

9 Wall Street research analysts have issued twelve-month target prices for Immunocore's stock. Their IMCR share price forecasts range from $67.00 to $90.00. On average, they expect the company's share price to reach $79.13 in the next twelve months. This suggests a possible upside of 26.8% from the stock's current price.
View analysts price targets for IMCR
or view top-rated stocks among Wall Street analysts.

How have IMCR shares performed in 2023?

Immunocore's stock was trading at $57.07 at the start of the year. Since then, IMCR stock has increased by 9.4% and is now trading at $62.41.
View the best growth stocks for 2023 here
.

Are investors shorting Immunocore?

Immunocore saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 1,920,000 shares, an increase of 39.1% from the December 31st total of 1,380,000 shares. Based on an average trading volume of 394,000 shares, the short-interest ratio is presently 4.9 days. Currently, 4.1% of the company's shares are short sold.
View Immunocore's Short Interest
.

When is Immunocore's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our IMCR earnings forecast
.

How were Immunocore's earnings last quarter?

Immunocore Holdings plc (NASDAQ:IMCR) issued its quarterly earnings results on Wednesday, November, 9th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.40. The company earned $48.52 million during the quarter, compared to analysts' expectations of $37.73 million. Immunocore had a negative trailing twelve-month return on equity of 29.53% and a negative net margin of 59.17%.

When did Immunocore IPO?

(IMCR) raised $199 million in an IPO on Friday, February 5th 2021. The company issued 8,300,000 shares at a price of $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies served as the underwriters for the IPO.

What is Immunocore's stock symbol?

Immunocore trades on the NASDAQ under the ticker symbol "IMCR."

Who are Immunocore's major shareholders?

Immunocore's stock is owned by many different retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.22%), CWM LLC (0.14%), Capital CS Group LLC (0.01%), JTC Employer Solutions Trustee Ltd (0.01%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Immunocore?

Shares of IMCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immunocore's stock price today?

One share of IMCR stock can currently be purchased for approximately $62.41.

How much money does Immunocore make?

Immunocore (NASDAQ:IMCR) has a market capitalization of $2.74 billion and generates $35.80 million in revenue each year. The company earns $-180,860,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis.

How many employees does Immunocore have?

The company employs 324 workers across the globe.

How can I contact Immunocore?

Immunocore's mailing address is 92 PARK DRIVE MILTON PARK ABINGDON, OXFORDSHIRE X0, OX14 4RY. The official website for the company is www.immunocore.com. The company can be reached via phone at 44-12-3543-8600 or via email at ir@immunocore.com.

This page (NASDAQ:IMCR) was last updated on 2/2/2023 by MarketBeat.com Staff